Merck
  • Home
  • Search Results
  • The cytochrome P450 epoxygenase pathway regulates the hepatic inflammatory response in fatty liver disease.

The cytochrome P450 epoxygenase pathway regulates the hepatic inflammatory response in fatty liver disease.

PloS one (2014-10-14)
Robert N Schuck, Weibin Zha, Matthew L Edin, Artiom Gruzdev, Kimberly C Vendrov, Tricia M Miller, Zhenghong Xu, Fred B Lih, Laura M DeGraff, Kenneth B Tomer, H Michael Jones, Liza Makowski, Leaf Huang, Samuel M Poloyac, Darryl C Zeldin, Craig R Lee
ABSTRACT

Fatty liver disease is an emerging public health problem without effective therapies, and chronic hepatic inflammation is a key pathologic mediator in its progression. Cytochrome P450 (CYP) epoxygenases metabolize arachidonic acid to biologically active epoxyeicosatrienoic acids (EETs), which have potent anti-inflammatory effects. Although promoting the effects of EETs elicits anti-inflammatory and protective effects in the cardiovascular system, the contribution of CYP-derived EETs to the regulation of fatty liver disease-associated inflammation and injury is unknown. Using the atherogenic diet model of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH), our studies demonstrated that induction of fatty liver disease significantly and preferentially suppresses hepatic CYP epoxygenase expression and activity, and both hepatic and circulating levels of EETs in mice. Furthermore, mice with targeted disruption of Ephx2 (the gene encoding soluble epoxide hydrolase) exhibited restored hepatic and circulating EET levels and a significantly attenuated induction of hepatic inflammation and injury. Collectively, these data suggest that suppression of hepatic CYP-mediated EET biosynthesis is an important pathological consequence of fatty liver disease-associated inflammation, and that the CYP epoxygenase pathway is a central regulator of the hepatic inflammatory response in NAFLD/NASH. Future studies investigating the utility of therapeutic strategies that promote the effects of CYP-derived EETs in NAFLD/NASH are warranted.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Rabbit anti-GAPDH Antibody, Affinity Purified, Powered by Bethyl Laboratories, Inc.
Sigma-Aldrich
Anti-GAPDH antibody, Mouse monoclonal, clone GAPDH-71.1, purified from hybridoma cell culture
Sigma-Aldrich
Citric acid trisodium salt, anhydrous, ≥98% (GC)
Sigma-Aldrich
Citrate Concentrated Solution, BioUltra, for molecular biology, 1 M in H2O
Sigma-Aldrich
Monoclonal Anti-GAPDH antibody produced in mouse, clone 3C2, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-GAPDH antibody produced in rabbit, ~1 mg/mL, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
Citrate Concentrated Solution, BioReagent, suitable for coagulation assays, 4 % (w/v)
Sigma-Aldrich
Anti-GAPDH antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Goat anti-GAPDH Antibody, Affinity Purified, Powered by Bethyl Laboratories, Inc.
Sigma-Aldrich
Anti-GAPDH antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-GAPDH antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
Supelco
Sodium Citrate, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Anti-GAPDH antibody produced in rabbit, affinity isolated antibody